132 related articles for article (PubMed ID: 15713894)
1. Gonadotropin-releasing hormone receptor-targeted gene therapy of gynecologic cancers.
Gründker C; Huschmand Nia A; Emons G
Mol Cancer Ther; 2005 Feb; 4(2):225-31. PubMed ID: 15713894
[TBL] [Abstract][Full Text] [Related]
2. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer.
Gründker C; Emons G
Reprod Biol Endocrinol; 2003 Oct; 1():65. PubMed ID: 14594454
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase C-independent stimulation of activator protein-1 and c-Jun N-terminal kinase activity in human endometrial cancer cells by the LHRH agonist triptorelin.
Gründker C; Schlotawa L; Viereck V; Emons G
Eur J Endocrinol; 2001 Nov; 145(5):651-8. PubMed ID: 11720885
[TBL] [Abstract][Full Text] [Related]
4. Gonadotropin-releasing hormone (GnRH) agonist triptorelin inhibits estradiol-induced serum response element (SRE) activation and c-fos expression in human endometrial, ovarian and breast cancer cells.
Gründker C; Günthert AR; Hellriegel M; Emons G
Eur J Endocrinol; 2004 Nov; 151(5):619-28. PubMed ID: 15538941
[TBL] [Abstract][Full Text] [Related]
5. Transcript and protein profiling identifies signaling, growth arrest, apoptosis, and NF-κB survival signatures following GNRH receptor activation.
Meyer C; Sims AH; Morgan K; Harrison B; Muir M; Bai J; Faratian D; Millar RP; Langdon SP
Endocr Relat Cancer; 2013 Feb; 20(1):123-36. PubMed ID: 23202794
[TBL] [Abstract][Full Text] [Related]
6. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
Gründker C; Völker P; Schulz KD; Emons G
Gynecol Oncol; 2000 Aug; 78(2):194-202. PubMed ID: 10926802
[TBL] [Abstract][Full Text] [Related]
7. GnRH antagonists in the treatment of gynecological and breast cancers.
Emons G; Gründker C; Günthert AR; Westphalen S; Kavanagh J; Verschraegen C
Endocr Relat Cancer; 2003 Jun; 10(2):291-9. PubMed ID: 12790790
[TBL] [Abstract][Full Text] [Related]
8. Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor.
Gründker C; Schlotawa L; Viereck V; Eicke N; Horst A; Kairies B; Emons G
Eur J Endocrinol; 2004 Jul; 151(1):141-9. PubMed ID: 15248835
[TBL] [Abstract][Full Text] [Related]
9. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation.
Gründker C; Günthert AR; Millar RP; Emons G
J Clin Endocrinol Metab; 2002 Mar; 87(3):1427-30. PubMed ID: 11889221
[TBL] [Abstract][Full Text] [Related]
10. Biology of the gonadotropin-releasing hormone system in gynecological cancers.
Gründker C; Günthert AR; Westphalen S; Emons G
Eur J Endocrinol; 2002 Jan; 146(1):1-14. PubMed ID: 11751060
[TBL] [Abstract][Full Text] [Related]
11. Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells.
Fister S; Schlotawa L; Günthert AR; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jan; 24(1):24-9. PubMed ID: 17943530
[TBL] [Abstract][Full Text] [Related]
12. [Effect of gonadotropin-releasing hormone-I agonist and gonadotropin-releasing hormone-II on endometrial carcinoma cell lines with different states of PTEN].
Zhao LJ; Wei LH; Li XP; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2009 Jan; 44(1):45-9. PubMed ID: 19563062
[TBL] [Abstract][Full Text] [Related]
13. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
Engel J; Emons G; Pinski J; Schally AV
Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
[TBL] [Abstract][Full Text] [Related]
14. Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo.
Schubert A; Hawighorst T; Emons G; Gründker C
Breast Cancer Res Treat; 2011 Dec; 130(3):783-90. PubMed ID: 21279682
[TBL] [Abstract][Full Text] [Related]
15. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.
Emons G; Sindermann H; Engel J; Schally AV; Gründker C
Neuroendocrinology; 2009; 90(1):15-8. PubMed ID: 19521066
[TBL] [Abstract][Full Text] [Related]
16. Signalling and anti-proliferative effects mediated by gonadotrophin-releasing hormone receptors after expression in prostate cancer cells using recombinant adenovirus.
Franklin J; Hislop J; Flynn A; McArdle CA
J Endocrinol; 2003 Feb; 176(2):275-84. PubMed ID: 12553876
[TBL] [Abstract][Full Text] [Related]
17. Effects of LHRH-analogues on mitogenic signal transduction in cancer cells.
Emons G; Müller V; Ortmann O; Schulz KD
J Steroid Biochem Mol Biol; 1998 Apr; 65(1-6):199-206. PubMed ID: 9699874
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.
Gründker C; Völker P; Emons G
Endocrinology; 2001 Jun; 142(6):2369-80. PubMed ID: 11356684
[TBL] [Abstract][Full Text] [Related]
19. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
[TBL] [Abstract][Full Text] [Related]
20. Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen.
Günthert AR; Gründker C; Olota A; Läsche J; Eicke N; Emons G
Eur J Endocrinol; 2005 Oct; 153(4):613-25. PubMed ID: 16189183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
